New drug combo aims to outsmart resistant lung cancer
NCT ID NCT07518160
First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This Phase II trial tests a combination of two drugs, JS212 and JS111, in about 35 people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to prior treatment. The study will first find the safest dose, then check how well the combination shrinks tumors and controls the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS212 (injection) and JS111 (capsules)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced lung cancer whose current therapy has stopped working.
- What could go wrong
- This is an early Phase II trial with only 35 participants, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China